Skip to content

Real-world study of topical analgesics in the treatment of myofascial pain syndrome

Real-world study of topical analgesics in the treatment of myofascial pain syndrome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054756
Enrollment
Unknown
Registered
2021-12-26
Start date
2021-12-31
Completion date
Unknown
Last updated
2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myofasciitis

Interventions

Group 1:shock wave +TENS, combined with Loxoprofen Sodium Cataplasms
Group 2:Loxoprofen Sodium Cataplasms
Group 3:shock wave +TENS
Group 4:shock wave +TENS, combined with Flurbiprofen Cataplasms

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Obvious neck, shoulder, thoracic, waist, and back pain, meeting the diagnostic criteria for myofascial pain syndrome. Exclude trauma and other organic lesions of the cervical, thoracic and lumbar spine by imaging examination, and there is no rheumatism, rheumatoid, ankylosing spondylitis, etc.; 2. Aged 18-75 years, gender is not limited; 3. Not taking other therapeutic drugs such as analgesics, hormones, surgical treatment and physical therapy within 1 month; 4. No history of bleeding, asthma, severe heart, liver and kidney insufficiency, non-steroidal drug allergy, etc.; 5. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women or women of childbearing age who are about to conceive; 2. Patients who have participated in clinical studies of other drugs within 1 month; other concomitant diseases or complications that may affect the observation of efficacy (local skin breakage, infection; rash).

Design outcomes

Primary

MeasureTime frame
pain score;

Countries

China

Contacts

Public ContactHuang Dong

The Third Xiangya Hospital of Central South University

438774332@qq.com+86 15874001647

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026